Page 131 - 《中国药房》2025年20期
P. 131

香连丸治疗溃疡性结肠炎的临床及分子机制研究进展
                                                                                            Δ


                                                  2 #
          李 莹 ,张早育 ,邓 蓉 ,陈佳乐 ,李彦龙 (1.甘肃中医药大学中西医结合学院,兰州 730000;2.甘肃省中医
                 1*
                          1
                                          1
                                  1
          院脾胃病诊疗中心,兰州 730050)
          中图分类号  R965;R969;R975      文献标志码  A      文章编号  1001-0408(2025)20-2609-06
          DOI  10.6039/j.issn.1001-0408.2025.20.22

          摘  要  溃疡性结肠炎(UC)是一种慢性肠道自身免疫性疾病,以腹痛、腹泻、黏液便和血便等为主要临床表现,发病机制复杂。
          经典名方香连丸(XLP)近年来被广泛应用于UC的临床治疗,其不良反应较少,患者耐受性好,具有明显临床应用潜力,但其临床
          研究、分子机制方面的证据尚未得以全面整合。本文通过系统综述XLP在UC治疗中的临床研究及分子机制发现,XLP及其加减
          方与化学药联用,可显著改善UC患者症状、减轻肠道炎症,效果优于单用化学药。该方改善UC的分子机制涉及调节泛凋亡、免
          疫反应、相关信号通路(缺氧诱导因子1α、核因子κB等)、肠道菌群和修复肠黏膜屏障等,其组方药材、单体和活性成分还可通过
          调节Wnt/β-联蛋白、Janus激酶/信号转导及转录活化因子等多条信号通路来阻碍辅助性T细胞17分化,恢复M1/M2型细胞平衡,
          减轻UC肠道损伤。
          关键词  香连丸;溃疡性结肠炎;临床研究;分子机制;研究进展

          Research  progress  on  clinical  and  molecular  mechanisms  of  Xianglian  pills  in  the  treatment  of  ulcerative
          colitis

          LI Ying ,ZHANG Zaoyu ,DENG Rong ,CHEN Jiale ,LI Yanlong(1.  School  of  Integrated  Traditional  Chinese
                                                         1
                                                                     2
                                             1
                                1
                1
          and Western Medicine, Gansu University of Chinese Medicine, Lanzhou 730000, China;2. Spleen and Stomach
          Disease  Diagnosis  and  Treatment  Center,  Gansu  Provincial  Hospital  of  Traditional  Chinese  Medicine,  Lanzhou
          730050, China)
          ABSTRACT   Ulcerative colitis (UC) is a chronic intestinal autoimmune disease, with clinical manifestations including abdominal

          pain, diarrhea, mucus and bloody stools, and its pathogenesis is complex. The classic prescription Xianglian pills (XLP) has been
          widely  used  in  the  clinical  treatment  of  UC  in  recent  years.  It  has  few  adverse  reactions,  good  patient  tolerance,  and  shows
          significant  potential  for  clinical  application.  However,  there  is  currently  no  comprehensive  integration  of  evidence  on  its  clinical
          research and molecular mechanisms. Through a systematic review of the clinical research and molecular mechanisms of XLP in the
          treatment of UC, it is found that XLP and its modified formulas, when used in combination with chemical drugs, can significantly
          improve the symptoms of UC patients and reduce intestinal inflammation, with superior efficacy compared to chemical drugs alone.
          Its  mechanism  of  action  involves  regulating  pan-apoptosis,  immune  response,  signaling  pathways (hypoxia-inducible  factor-1α,
          nuclear factor-κB, etc.), intestinal flora, and repairing the intestinal mucosal barrier. Its medicinal materials, monomers and active
          components  can  also  prevent  the  differentiation  of  helper  T  cells  17  and  restore  the  balance  of  M1/M2  cells  through  regulating
          multiple  pathways  such  as  Wnt/β -catenin  and  Janus  kinase/signal  transducer  and  activator  of  transcription,  thereby  reducing
          intestinal damage in UC.
          KEYWORDS    Xianglian pills; ulcerative colitis; clinical research; molecular mechanism; research progress


             Δ 基金项目 甘肃省自然科学基金项目(No.21JR11RA205);甘肃
                                                                 溃疡性结肠炎(ulcerative colitis,UC)是炎症性肠病
          省青年科技基金计划项目(No.18JR3RA072);第二批陇原青年英才
          项目                                                 的主要类型之一,是一种局限于黏膜及黏膜下层的慢性
             *第一作者 硕士研究生。研究方向:中西医结合防治消化道疾                    肠道自身免疫性疾病,以腹痛、腹泻、黏液便和血便等为
          病。E-mail:1794993738@qq.com                                 [1]
                                                             常见症状 。尽管UC病因尚不明确,但学界普遍认为其
             # 通信作者 副主任医师,硕士生导师,硕士。研究方向:胆胰疾病
                                                             发病机制主要涉及遗传易感性、环境暴露、肠道菌群紊
          内镜治疗、消化道疾病的中西医结合诊治。E-mail:18298470326@
                                                                                            [2]
          163.com                                            乱、肠上皮损伤和免疫失调等方面 。当前,临床治疗

          中国药房  2025年第36卷第20期                                              China Pharmacy  2025 Vol. 36  No. 20    · 2609 ·
   126   127   128   129   130   131   132   133   134   135   136